Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Pfizer completes case accrual for new Prevenar 13 trial

Pfizer completes case accrual for new Prevenar 13 trial

2nd September 2013

Pfizer has announced the completion of pneumonia case accrual in a new study of a Prevenar 13 vaccine trial called CAPiTA.

The study is the largest of its kind and aims to assess whether Prevenar 13 is effective in preventing community-acquired pneumonia caused by the 13 pneumococcal serotypes included in the vaccine among patients over the age of 65.

Because it is an event-driven study, a prespecified number of community-acquired, vaccine-type pneumococcal pneumonia cases have to occur among study participants before the results can be determined.

All remaining suspected cases currently in review will now be fully processed to allow the database to be locked, a process that will be carried out by Julius Clinical and is expected to take several months to complete.

Pfizer and Julius Clinical will be able to deliver top-line results from the study in early 2014.

This comes after the firm signed a new supply agreement with the GAVI Alliance in July 2013 to provide additional doses of Prevenar 13 for use among infants and young children in the world's poorest countries.ADNFCR-8000103-ID-801632150-ADNFCR

We currently have 9 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.